Literature DB >> 12804137

Safety and efficiency of modulating paracellular permeability to enhance airway epithelial gene transfer in vivo.

Larry G Johnson1, Miriam K Vanhook, Carolyn B Coyne, Najwa Haykal-Coates, Stephen H Gavett.   

Abstract

We evaluated the safety of agents that enhance gene transfer by modulating paracellular permeability. Lactate dehydrogenase (LDH) and cytokine release were measured in polarized primary human airway epithelial (HAE) cells after lumenal application of vehicle, ethyleneglycol-bis-(beta-aminoethyl ether)-N,N'-tetraacetic acid (EGTA), sodium caprate (C10), or sodium laurate (C12). Lung toxicity was assessed after tracheobronchial instillation to murine airways and the relative ability of these agents to enhance in vivo adenoviral gene transfer was evaluated. Lumenal C12 increased LDH release in vitro, but C10 and EGTA did not. Increased levels of interleukin 8 (IL-8) were secreted from EGTA-pretreated cystic fibrosis HAE cells after apical application of Pseudomonas aeruginosa (10(8) CFU/ml), whereas IL-8 secretion from C10- and C12-pretreated cells was not different from controls. In vivo toxicity studies demonstrated no effect of EGTA, C10, or C12 on weight gain, lung edema, or bronchoalveolar lavage fluid (BALF) albumin. EGTA increased BALF cell counts, neutrophils, and murine (m) macrophage inflammatory protein 2, mKC, mIL-6, and mIL-1 beta levels. C10 had no effect on BALF cell counts or LDH, but increased murine tumor necrosis factor alpha. C12 increased BALF LDH, neutrophils, and mIL-6 levels. Histopathological analysis revealed mild focal lung inflammation more frequently in the EGTA, C10, and C12 groups than in vehicle controls, with greater intensity in the C12 group relative to the other groups. C10 and C12 also increased airway responsiveness to methacholine challenge compared with control and EGTA groups. Adenoviral gene transfer to murine trachea in vivo was enhanced more efficiently by C10 than by C12 or EGTA. Thus, the different toxicities may permit the selection of agents that enhance gene transfer with minimal adverse effects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804137     DOI: 10.1089/104303403765255138

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  12 in total

1.  Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes.

Authors:  Katsuyuki Mitomo; Uta Griesenbach; Makoto Inoue; Lucinda Somerton; Cuixiang Meng; Eiji Akiba; Toshiaki Tabata; Yasuji Ueda; Gad M Frankel; Raymond Farley; Charanjit Singh; Mario Chan; Felix Munkonge; Andrea Brum; Stefania Xenariou; Sara Escudero-Garcia; Mamoru Hasegawa; Eric W F W Alton
Journal:  Mol Ther       Date:  2010-03-23       Impact factor: 11.454

Review 2.  Effective viral-mediated lung gene therapy: is airway surface preparation necessary?

Authors:  David Parsons; Martin Donnelley; Alexandra McCarron; Patricia Cmielewski; Victoria Drysdale
Journal:  Gene Ther       Date:  2022-03-29       Impact factor: 4.184

Review 3.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

4.  High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors.

Authors:  Manij Patel; Angela M Giddings; John Sechelski; John C Olsen
Journal:  J Gene Med       Date:  2013-01       Impact factor: 4.565

5.  Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase.

Authors:  Igor B Gubrij; Sara Rebecca Martin; Amanda K Pangle; Richard Kurten; Larry G Johnson
Journal:  Hum Gene Ther       Date:  2014-03-26       Impact factor: 5.695

6.  An impaired alveolar-capillary barrier in vitro: effect of proinflammatory cytokines and consequences on nanocarrier interaction.

Authors:  Maria Iris Hermanns; Jennifer Kasper; Peter Dubruel; Christine Pohl; Chiara Uboldi; Vincent Vermeersch; Sabine Fuchs; Ronald E Unger; C James Kirkpatrick
Journal:  J R Soc Interface       Date:  2009-09-30       Impact factor: 4.118

7.  In vitro interactions between the oral absorption promoter, sodium caprate (C(10)) and S. typhimurium in rat intestinal ileal mucosae.

Authors:  Alyssa B Cox; Lee-Anne Rawlinson; Alan W Baird; Victoria Bzik; David J Brayden
Journal:  Pharm Res       Date:  2007-06-02       Impact factor: 4.200

8.  Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice.

Authors:  Rachida Legssyer; François Huaux; Jean Lebacq; Monique Delos; Etienne Marbaix; Patrick Lebecque; Dominique Lison; Bob J Scholte; Pierre Wallemacq; Teresinha Leal
Journal:  Respir Res       Date:  2006-10-25

9.  RAS transformation requires CUX1-dependent repair of oxidative DNA damage.

Authors:  Zubaidah M Ramdzan; Charles Vadnais; Ranjana Pal; Guillaume Vandal; Chantal Cadieux; Lam Leduy; Sayeh Davoudi; Laura Hulea; Lu Yao; Anthony N Karnezis; Marilène Paquet; David Dankort; Alain Nepveu
Journal:  PLoS Biol       Date:  2014-03-11       Impact factor: 8.029

10.  A modular lentiviral and retroviral construction system to rapidly generate vectors for gene expression and gene knockdown in vitro and in vivo.

Authors:  Benjamin Geiling; Guillaume Vandal; Ada R Posner; Angeline de Bruyns; Kendall L Dutchak; Samantha Garnett; David Dankort
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.